GammaCore Sapphire, a new non-invasive hand-held device for migraine and episodic cluster headache treatment, has been made available by electroCore.
Teva has decided to discontinue part of the ENFORCE Phase 3 clinical development program for fremanezumab.
The episodic cluster headache trial included a total of 106 patients with an average of 17.5 cluster headache attacks per week at baseline.
Over half of all individuals included in this study reported headache attacks occurring at specific time periods throughout the day.
The 2 treatments for cluster headache with Level A recommendations are either not readily accessible via public or private insurance or are not recommended in a large subset of patients with cardiovascular disease.
Despite a recent study concluding that oxygen therapy for cluster headache is not cost-prohibitive, many private payers and Medicare and Medicaid do not cover the effective therapy. Matthew Robbins, MD, Stewart Tepper, MD, and others weigh in on the controversial decision.
Painful signs and symptoms frequently occur prior to cluster headache attacks.
The current costs of medical grade oxygen for treating cluster headache are not "prohibitively expensive."
Patients can receive the gammaCore device by participating in the gammaCore Patient Registry program.
A follow-up study revealed the benefits of sphenopalatine ganglion stimulation for the prevention of cluster headache attacks.
Acupuncture, neurostimulation, and other alternative treatments have been associated with up to a 50% reduction in headache days.
SPG stimulation is delivered on-demand through an implanted neurostimulator.
The therapy effects lasted for about a month, as researchers noted the procedure would need to be repeated for continuous relief.
The noninvasive device not only stopped acute attacks, but reduced overall headache frequency.
Neurology Advisor Articles
- Rasagiline Plus Riluzole is Safe, May Improve Survival in ALS
- Treatment of New-Onset Epilepsy: AAN, AES Update Practice Guidelines
- Gender Differences in the Epidemiology of Migraine
- Changes in Glucose Regulation in Parkinson Disease
- Apomorphine Infusions Improves Off Time Associated With Parkinson Disease
- Some Statins May Be Associated With Cognition, Memory Deficits
- Neuropathic Pain Treatments
- Cannabis for Multiple Sclerosis: Prescriber's Perspective
- New Monoclonal Antibody BAN2401 Reduces Amyloid Plaques, Improves Cognition in Alzheimer's
- Nonpharmacologic Interventions for Alzheimer's Have Greater Impact on Outcomes Than Currently Available Medications
- Locally Asymptomatic Ischemic Stroke May Present as Migraine Aura
- Associations Identified Between Stroke Severity, Recovery of Visuospatial Neglect
- Action Tremor May Have Central Origin in Motor Neuron Disease
- Characteristics Affecting Health-Related Quality of Life in RRMS, Progressive MS
- Neurodevelopmental Anomalies, Birth Defects Linked to Zika ID'd